Which prescription medication (Rx) should be ordered for constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prescription Medication for Constipation

Start with polyethylene glycol (PEG) 17 g once daily as your first-line prescription for chronic constipation—it is the gold standard based on superior efficacy, safety, cost-effectiveness, and proven long-term durability. 1

First-Line Prescription: Polyethylene Glycol (PEG)

PEG 17 g daily is the definitive first-line choice recommended by the American Gastroenterological Association for chronic idiopathic constipation. 1 This osmotic laxative works by drawing water into the intestine to increase stool bulk and facilitate passage. 2

Dosing Algorithm for PEG

  • Initial dose: 17 g once daily, mixed in 4-8 ounces of liquid 2
  • If inadequate response after 2-3 days: Increase to 17 g twice daily (34 g total daily dose) 2
  • Titration: Continue adjusting dose upward based on clinical response with no clear maximum dose 1, 2
  • Treatment goal: Achieve one non-forced bowel movement every 1-2 days 2
  • Duration: PEG has proven durability and safety for 6 months or longer of continuous use 2

Key Clinical Considerations for PEG

  • Ensure adequate hydration while on PEG therapy, particularly in patients with low baseline fluid intake 2
  • Common side effects include abdominal distension, loose stools, flatulence, and nausea 2
  • Monthly cost is $10-$45, making it highly cost-effective compared to prescription secretagogues 2

Alternative First-Line Osmotic Laxatives

If PEG is not tolerated or unavailable:

  • Magnesium oxide 400-500 mg daily can be used, but exercise caution in renal insufficiency and pregnancy 1
  • Lactulose 15 g daily is another option, though bloating and flatulence may limit tolerability 1

Second-Line Prescription Options: Stimulant Laxatives

Use stimulant laxatives only for short-term rescue therapy or when osmotic laxatives provide inadequate response. 1

  • Bisacodyl 5 mg daily (maximum 10 mg daily) for short-term use 1
    • Note: Bisacodyl produces the greatest increase in bowel movements (6.8 spontaneous bowel movements per week after eliminating placebo effect) but shows the most noticeable loss of efficacy between week 1 and week 4 3
  • Senna 8.6-17.2 mg daily (maximum 4 tablets twice daily) as second-line treatment, though long-term safety and efficacy data are limited 1

Important Caveat on Stimulant Laxatives

Stimulant laxatives are exclusively designated for as-needed use, not chronic daily therapy. 4 Reserve these for rescue situations or when osmotic laxatives fail.

Third-Line Prescription Options: Secretagogues and Prokinetics

For refractory cases that fail PEG and stimulant laxatives, consider prescription secretagogues or prokinetic agents. 1

Secretagogues (Intestinal Fluid Secretion Enhancers)

  • Lubiprostone 24 mcg twice daily increases intestinal secretion and may provide additional benefit for abdominal pain 1
  • Linaclotide 72-145 mcg daily (maximum 290 mcg daily) is a guanylate cyclase-C agonist that increases intestinal secretion and may benefit abdominal pain 1, 5
    • Linaclotide is appropriate as first-line prescription treatment specifically for IBS-C, but for chronic idiopathic constipation, osmotic laxatives should be tried first due to considerably lower cost 6
  • Plecanatide 3 mg daily (no titration needed) is another guanylate cyclase-C agonist for refractory cases 1
    • Note: Plecanatide yields the lowest increase in bowel movements among prescription agents (approximately 4 times less than bisacodyl) 3

Prokinetic Agent

  • Prucalopride 1-2 mg daily (maximum 2 mg daily) is a serotonin type 4 (5-HT4) receptor agonist that enhances colonic motility and may provide additional benefit for abdominal pain 1, 5

Treatment Algorithm Summary

  1. Start with PEG 17 g daily as the most cost-effective option with best evidence for long-term use 1
  2. If inadequate response after 2-3 days: Titrate PEG dose upward 1
  3. If PEG alone fails: Add or switch to stimulant laxatives (bisacodyl or senna) for short-term use 1
  4. Before escalating to prescription secretagogues: Rule out fecal impaction and bowel obstruction 2
  5. For refractory cases: Consider prescription secretagogues (lubiprostone, linaclotide, plecanatide) or prokinetic agent (prucalopride) 1
  6. At 4 weeks: If no improvement despite maximum therapy, reassess and consider switching agents 5

Common Pitfalls to Avoid

  • Do not prescribe docusate (stool softener) for established constipation—it is ineffective and not recommended 2
  • Avoid supplemental fiber (psyllium) for established constipation, as it may worsen symptoms 2
  • Do not use stimulant laxatives as chronic daily therapy—they are for short-term or as-needed use only 1, 4
  • Ensure adequate hydration with any constipation therapy to optimize efficacy 5, 2

Supporting Dietary Measures

While not prescription medications, advise patients to maintain adequate fiber intake of 14 g per 1,000 kcal daily, as fiber supplementation can help with chronic constipation when combined with pharmacotherapy. 1

References

Guideline

Management of Chronic Constipation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Polyethylene Glycol (PEG) Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

AGA‑ACG Guideline Context and Recommendations for Elobixibat in Chronic Idiopathic Constipation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.